BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep. 2020;10:16425. [PMID: 33009477 DOI: 10.1038/s41598-020-73525-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Conti G, Pitea M, Ossanna R, Opri R, Tisci G, Falvo E, Innamorati G, Ghanem E, Sbarbati A, Ceci P, Fracasso G. Mitoxantrone-Loaded Nanoferritin Slows Tumor Growth and Improves the Overall Survival Rate in a Subcutaneous Pancreatic Cancer Mouse Model. Biomedicines 2021;9:1622. [PMID: 34829851 DOI: 10.3390/biomedicines9111622] [Reference Citation Analysis]
2 Andreasson C, Ansari D, Ekbom F, Andersson R. Macropinocytosis: the Achilles' heel of pancreatic cancer? Scand J Gastroenterol 2021;56:177-9. [PMID: 33280476 DOI: 10.1080/00365521.2020.1855471] [Reference Citation Analysis]
3 Wheeldon L, Jones M, Probyn B, Shetty D, Garvican J. Use of the Biocartis Idylla™ Platform for the Detection of Epidermal Growth Factor Receptor, BRAF and KRAS Proto-Oncogene Mutations in Liquid-Based Cytology Specimens from Patients with Non-Small Cell Lung Carcinoma and Pancreatic Adenocarcinoma. JMP 2022;3:104-14. [DOI: 10.3390/jmp3020010] [Reference Citation Analysis]
4 Huhta H, Nortunen M, Meriläinen S, Helminen O, Kauppila JH. Hospital volume and outcomes of pancreatic cancer: a Finnish population-based nationwide study. HPB (Oxford) 2021:S1365-182X(21)01665-8. [PMID: 34824013 DOI: 10.1016/j.hpb.2021.10.011] [Reference Citation Analysis]
5 Truong VG, Jeong S, Park JS, Tran VN, Kim SM, Lee DH, Kang HW. Endoscopic ultrasound (EUS)-guided cylindrical interstitial laser ablation (CILA) on in vivo porcine pancreas. Biomed Opt Express 2021;12:4423-37. [PMID: 34457423 DOI: 10.1364/BOE.427379] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hou P, Ma X, Yang Z, Zhang Q, Wu CJ, Li J, Tan L, Yao W, Yan L, Zhou X, Kimmelman AC, Lorenzi PL, Zhang J, Jiang S, Spring D, Wang YA, DePinho RA. USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer. Genes Dev 2021;35:1327-32. [PMID: 34531315 DOI: 10.1101/gad.348787.121] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hu JX, Zhao CF, Chen WB, Liu QC, Li QW, Lin YY, Gao F. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol 2021; 27(27): 4298-4321 [PMID: 34366606 DOI: 10.3748/wjg.v27.i27.4298] [Reference Citation Analysis]
8 Weyhe D, Obonyo D, Uslar V, Tabriz N. Effects of intensive physiotherapy on Quality of Life (QoL) after pancreatic cancer resection: a randomized controlled trial. BMC Cancer 2022;22:520. [PMID: 35534822 DOI: 10.1186/s12885-022-09586-1] [Reference Citation Analysis]
9 Tang P, Qu W, Wu D, Chen S, Liu M, Chen W, Ai Q, Tang H, Zhou H. Identifying and Validating an Acidosis-Related Signature Associated with Prognosis and Tumor Immune Infiltration Characteristics in Pancreatic Carcinoma. J Immunol Res 2021;2021:3821055. [PMID: 34993253 DOI: 10.1155/2021/3821055] [Reference Citation Analysis]
10 Liu R, Dollinger E, Nie Q. Machine Learning of Single Cell Transcriptomic Data From anti-PD-1 Responders and Non-responders Reveals Distinct Resistance Mechanisms in Skin Cancers and PDAC. Front Genet 2021;12:806457. [PMID: 35178072 DOI: 10.3389/fgene.2021.806457] [Reference Citation Analysis]
11 Tabriz N, Uslar VN, Obonyo D, Weyhe D. Micronutritional status after pylorus preserving duodenopancreatectomy: analysis of data from a randomized controlled trial. Sci Rep 2021;11:18475. [PMID: 34531424 DOI: 10.1038/s41598-021-97438-6] [Reference Citation Analysis]
12 Luo D, Xu X, Iqbal MZ, Zhao Q, Zhao R, Farheen J, Zhang Q, Zhang P, Kong X. siRNA-Loaded Hydroxyapatite Nanoparticles for KRAS Gene Silencing in Anti-Pancreatic Cancer Therapy. Pharmaceutics 2021;13:1428. [PMID: 34575504 DOI: 10.3390/pharmaceutics13091428] [Reference Citation Analysis]
13 Montemagno C, Cassim S, De Leiris N, Durivault J, Faraggi M, Pagès G. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine? Int J Mol Sci 2021;22:6413. [PMID: 34203923 DOI: 10.3390/ijms22126413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Pekarek L, Fraile-Martinez O, Garcia-Montero C, Saez MA, Barquero-Pozanco I, Del Hierro-Marlasca L, de Castro Martinez P, Romero-Bazán A, Alvarez-Mon MA, Monserrat J, García-Honduvilla N, Buján J, Alvarez-Mon M, Guijarro LG, Ortega MA. Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer. Cancers (Basel) 2022;14:1866. [PMID: 35454771 DOI: 10.3390/cancers14081866] [Reference Citation Analysis]
15 Jansen RJ, Orr M, Bamlet WR, Petersen GM. A Pilot Study of Blood-Based Methylation Markers Associated With Pancreatic Cancer. Front Genet 2022;13:849839. [DOI: 10.3389/fgene.2022.849839] [Reference Citation Analysis]
16 Kirchweger P, Kupferthaler A, Burghofer J, Webersinke G, Jukic E, Schwendinger S, Weitzendorfer M, Petzer A, Függer R, Rumpold H, Wundsam H. Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage. Eur J Surg Oncol 2021:S0748-7983(21)00947-1. [PMID: 34876329 DOI: 10.1016/j.ejso.2021.11.138] [Reference Citation Analysis]
17 Sakura K, Sasai M, Mino T, Uyama H. Non-Woven Sheet Containing Gemcitabine: Controlled Release Complex for Pancreatic Cancer Treatment. Polymers (Basel) 2022;14:168. [PMID: 35012190 DOI: 10.3390/polym14010168] [Reference Citation Analysis]
18 van Dam MA, Vuijk FA, Stibbe JA, Houvast RD, Luelmo SAC, Crobach S, Shahbazi Feshtali S, de Geus-Oei LF, Bonsing BA, Sier CFM, Kuppen PJK, Swijnenburg RJ, Windhorst AD, Burggraaf J, Vahrmeijer AL, Mieog JSD. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. Cancers (Basel) 2021;13:6088. [PMID: 34885196 DOI: 10.3390/cancers13236088] [Reference Citation Analysis]
19 Moik F, Prager G, Thaler J, Posch F, Wiedemann S, Schramm T, Englisch C, Mackman N, Pabinger I, Ay C. Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer. Arterioscler Thromb Vasc Biol 2021;41:2837-47. [PMID: 34470475 DOI: 10.1161/ATVBAHA.121.316463] [Reference Citation Analysis]
20 Hsu FT, Tsai CL, Chiang IT, Lan KH, Yueh PF, Liang WY, Lin CS, Chao Y, Lan KL. Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma. J Cell Mol Med 2022. [PMID: 35174623 DOI: 10.1111/jcmm.17220] [Reference Citation Analysis]
21 Kirchweger P, Kupferthaler A, Burghofer J, Webersinke G, Jukic E, Schwendinger S, Weitzendorfer M, Petzer A, Függer R, Rumpold H, Wundsam H. Data of ‘Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage’. Data in Brief 2022;41:107944. [DOI: 10.1016/j.dib.2022.107944] [Reference Citation Analysis]
22 Zhang X, Zeng Z, Liu H, Xu L, Sun X, Xu J, Song G. Recent development of a magneto-optical nanoplatform for multimodality imaging of pancreatic ductal adenocarcinoma. Nanoscale 2022;14:3306-23. [PMID: 35170601 DOI: 10.1039/d1nr08394e] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ewers KM, Patil S, Kopp W, Thomale J, Quilitz T, Magerhans A, Wang X, Hessmann E, Dobbelstein M. HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells. Cancers (Basel) 2021;13:6163. [PMID: 34944784 DOI: 10.3390/cancers13246163] [Reference Citation Analysis]
24 Khakoo S, Petrillo A, Salati M, Muhith A, Evangelista J, Seghezzi S, Petrelli F, Tomasello G, Ghidini M. Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome? Cancers (Basel) 2021;13:4396. [PMID: 34503206 DOI: 10.3390/cancers13174396] [Reference Citation Analysis]
25 Brown ZJ, Labiner HE, Shen C, Ejaz A, Pawlik TM, Cloyd JM. Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma. J Surg Oncol 2021. [PMID: 34599756 DOI: 10.1002/jso.26706] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Marin AM, Mattar SB, Amatuzzi RF, Chammas R, Uno M, Zanette DL, Aoki MN. Plasma Exosome-Derived microRNAs as Potential Diagnostic and Prognostic Biomarkers in Brazilian Pancreatic Cancer Patients. Biomolecules 2022;12:769. [DOI: 10.3390/biom12060769] [Reference Citation Analysis]
27 Botrus G, Uson Junior PLS, Raman P, Kaufman AE, Kosiorek H, Yin J, Fu Y, Majeed U, Sonbol MB, Ahn DH, Chang IW, Drusbosky LM, Dada H, Starr J, Borad M, Mody K, Bekaii-Saab TS. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Front Oncol 2021;11:794009. [PMID: 35083150 DOI: 10.3389/fonc.2021.794009] [Reference Citation Analysis]
28 Wu W, Liu Q, Zhang J, Zhao Y. Survey on the current status of the diagnosis and treatment of pancreatic cancer in public tertiary hospitals in China: a cross-sectional questionnaire-based, observational study. Journal of Pancreatology 2021;4:164-9. [DOI: 10.1097/jp9.0000000000000079] [Reference Citation Analysis]
29 Giannis D, Moris D, Barbas AS. Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians. Cancers (Basel) 2021;13:1071. [PMID: 33802340 DOI: 10.3390/cancers13051071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Zhang X, Li X, Xie J, Zhu Q, Yuan Y. A Novel Immune-Related Prognostic Signature Predicting Survival in Patients with Pancreatic Adenocarcinoma. J Oncol 2022;2022:8909631. [PMID: 35342420 DOI: 10.1155/2022/8909631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Amin S, Joo S, Nolte S, Yoo HK, Patel N, Byrnes HF, Costa-Cabral S, Johnson CD. Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values. BMC Cancer 2022;22:563. [PMID: 35596182 DOI: 10.1186/s12885-022-09661-7] [Reference Citation Analysis]
32 Servetto A, Santaniello A, Napolitano F, Foschini F, Marciano R, Cascetta P, Amato AR, Augurio MR, Maresca L, De Placido P, De Placido S, Formisano L, Bianco R. FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. Future Oncol 2022. [PMID: 35608115 DOI: 10.2217/fon-2021-1142] [Reference Citation Analysis]
33 Truong VG, Kim H, Park JS, Tran VN, Kang HW. Multiple cylindrical interstitial laser ablations (CILAs) of porcine pancreas in ex vivo and in vivo models. Int J Hyperthermia 2021;38:1313-21. [PMID: 34472992 DOI: 10.1080/02656736.2021.1972171] [Reference Citation Analysis]
34 Aziz MH, van Dongen JC, Saida L, Suker M, van Vugt JLA, van Putten Y, Sideras K, Groen JV, Mieog JSD, Lucassen CJ, Droop A, Mauff K, Shahbazi Feshtali S, Groot Koerkamp B, Mustafa DAM, van Eijck CJ. High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma. Front Oncol 2022;12:827755. [PMID: 35296013 DOI: 10.3389/fonc.2022.827755] [Reference Citation Analysis]
35 Gu X, Zhu Q, Tian G, Song W, Wang T, Wang A, Chen X, Qin S. KIF11 manipulates SREBP2-dependent mevalonate cross talk to promote tumor progression in pancreatic ductal adenocarcinoma. Cancer Med 2022. [PMID: 35619540 DOI: 10.1002/cam4.4683] [Reference Citation Analysis]
36 Mas L, Lupinacci RM, Cros J, Bachet JB, Coulet F, Svrcek M. Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights. Int J Mol Sci 2021;22:6756. [PMID: 34201897 DOI: 10.3390/ijms22136756] [Reference Citation Analysis]
37 Lupinacci RM, Faron M, Bachellier P, Sauvanet A, Beauchet A, Le Treut YP, Adham M, Mabrut JY, Delpero JR, Paye F. Acute Pancreatitis as the Initial Presentation of Pancreatic Adenocarcinoma does not Impact Short- and Long-term Outcomes of Curative Intent Surgery: A Study of the French Surgical Association. World J Surg 2021;45:3146-56. [PMID: 34191085 DOI: 10.1007/s00268-021-06205-1] [Reference Citation Analysis]
38 Cai H, Chen Y, Xu L, Zou Y, Zhou X, Liang G, Wang D, Tao Z. Differently PEGylated Polymer Nanoparticles for Pancreatic Cancer Delivery: Using a Novel Near-Infrared Emissive and Biodegradable Polymer as the Fluorescence Tracer. Front Bioeng Biotechnol 2021;9:699610. [PMID: 34268300 DOI: 10.3389/fbioe.2021.699610] [Reference Citation Analysis]
39 Ufuk A, Garner T, Stevens A, Latif A. Monocarboxylate Transporters Are Involved in Extracellular Matrix Remodelling in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2022;14:1298. [PMID: 35267606 DOI: 10.3390/cancers14051298] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Xiao Z, Li J, Yu Q, Zhou T, Duan J, Yang Z, Liu C, Xu F. An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma. Front Pharmacol 2021;12:778294. [PMID: 35002712 DOI: 10.3389/fphar.2021.778294] [Reference Citation Analysis]
41 Usai A, Di Franco G, Piccardi M, Cateni P, Pollina LE, Vivaldi C, Vasile E, Funel N, Palmeri M, Dente L, Falcone A, Giunchi D, Massolo A, Raffa V, Morelli L. Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. Cancers (Basel) 2021;13:4131. [PMID: 34439284 DOI: 10.3390/cancers13164131] [Reference Citation Analysis]
42 Nguyen LT, Nguyen HV, Do DH, Nguyen KT, Do AT, Pham HH, Nguyen CD. Survival in resectable pancreatic ductal adenocarcinoma with para-aortic lymph node dissection: A retrospective study in Vietnamese population. Ann Med Surg (Lond) 2021;65:102361. [PMID: 34026099 DOI: 10.1016/j.amsu.2021.102361] [Reference Citation Analysis]
43 Panebianco C, Ciardiello D, Villani A, Maiorano BA, Latiano TP, Maiello E, Perri F, Pazienza V. Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective. Semin Cancer Biol 2021:S1044-579X(21)00280-7. [PMID: 34838957 DOI: 10.1016/j.semcancer.2021.11.007] [Reference Citation Analysis]
44 Wang C, Chen H, Deng X, Xu W, Shen B. Real‐world implications of nonbiological factors with staging, clinical management, and prognostic prediction in pancreatic ductal adenocarcinoma. Cancer Medicine. [DOI: 10.1002/cam4.4910] [Reference Citation Analysis]
45 Timmer FEF, Geboers B, Nieuwenhuizen S, Dijkstra M, Schouten EAC, Puijk RS, de Vries JJJ, van den Tol MP, Bruynzeel AME, Streppel MM, Wilmink JW, van der Vliet HJ, Meijerink MR, Scheffer HJ, de Gruijl TD. Pancreatic Cancer and Immunotherapy: A Clinical Overview. Cancers (Basel) 2021;13:4138. [PMID: 34439292 DOI: 10.3390/cancers13164138] [Reference Citation Analysis]
46 Nicolle R, Gayet O, Bigonnet M, Roques J, Chanez B, Puleo F, Augustin J, Emile JF, Svrcek M, Arsenijevic T, Hammel P, Rebours V, Giovannini M, Grandval P, Dahan L, Moutardier V, Mitry E, Van Laethem JL, Bachet JB, Cros J, Iovanna J, Dusetti NJ. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer. Transl Oncol 2021;16:101315. [PMID: 34906890 DOI: 10.1016/j.tranon.2021.101315] [Reference Citation Analysis]
47 Ma X, Zou W, Sun Y. Prognostic Value of Pretreatment Controlling Nutritional Status Score for Patients With Pancreatic Cancer: A Meta-Analysis. Front Oncol 2022;11:770894. [DOI: 10.3389/fonc.2021.770894] [Reference Citation Analysis]
48 Nguyen LT, Do DH, Van Nguyen H, Nguyen KT, Nguyen CD. Lymph Node Characteristics and Short-Term Outcomes for Resectable Pancreatic Ductal Adenocarcinoma in Vietnam: A Retrospective Single-Center Study. Indian J Surg. [DOI: 10.1007/s12262-022-03344-0] [Reference Citation Analysis]
49 Kumar AA, Buckley BJ, Ranson M. The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets. Biomolecules 2022;12:152. [DOI: 10.3390/biom12020152] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Andersson R, Haglund C, Seppänen H, Ansari D. Pancreatic cancer - the past, the present, and the future. Scand J Gastroenterol 2022;:1-9. [PMID: 35477331 DOI: 10.1080/00365521.2022.2067786] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Al Faruque H, Choi ES, Kim JH, Kim E. Enhanced effect of autologous EVs delivering paclitaxel in pancreatic cancer. J Control Release 2022;347:330-46. [PMID: 35561870 DOI: 10.1016/j.jconrel.2022.05.012] [Reference Citation Analysis]
52 Markowski A, Jaromin A, Migdał P, Olczak E, Zygmunt A, Zaremba-Czogalla M, Pawlik K, Gubernator J. Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells. Int J Mol Sci 2022;23:5536. [PMID: 35628352 DOI: 10.3390/ijms23105536] [Reference Citation Analysis]
53 Xu Y, Du J, Wang Y, Gong B, Wang Y, Qian L, Tan Y. A Highly Responsive Pancreatic Ductal Adenocarcinoma with Liver Metastasis: A Rare Case Report. Int J Gen Med 2021;14:487-96. [PMID: 33623421 DOI: 10.2147/IJGM.S293806] [Reference Citation Analysis]
54 Bengtsson A, Andersson R, Rahm J, Ganganna K, Andersson B, Ansari D. Organoid technology for personalized pancreatic cancer therapy. Cell Oncol (Dordr). 2021;44:251-260. [PMID: 33492660 DOI: 10.1007/s13402-021-00585-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
55 Zhang Z, Zhu R, Sun W, Wang J, Liu J. Analysis of Methylation-driven Genes in Pancreatic Ductal Adenocarcinoma for Predicting Prognosis. J Cancer 2021;12:6507-18. [PMID: 34659542 DOI: 10.7150/jca.53208] [Reference Citation Analysis]